Aarhus University Seal

Anders Hammerich Riis

Preadmission glucocorticoid use and anastomotic leakage after colon and rectal cancer resections: a Danish cohort study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Preadmission glucocorticoid use and anastomotic leakage after colon and rectal cancer resections : a Danish cohort study. / Ostenfeld, Eva Bjerre; Erichsen, Rune; Baron, John A et al.

In: BMJ Open, Vol. 5, No. 9, 2015, p. e008045.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{042cbc6fadc745d199177444f1d0a6c4,
title = "Preadmission glucocorticoid use and anastomotic leakage after colon and rectal cancer resections: a Danish cohort study",
abstract = "OBJECTIVE: To examine whether preadmission glucocorticoid use increases the risk of anastomotic leakage after colon and rectal cancer resections.DESIGN: A population-based cohort study.SETTING: Denmark (2001-2011).PARTICIPANTS: We identified patients who had undergone a primary anastomosis after a colorectal cancer resection by linking medical registries. Participants who filled their most recent glucocorticoid prescription ≤90, 91-365 and >365 days before their surgery date were categorised as current, recent and former users, respectively.MAIN OUTCOME MEASURES: We calculated 30-day absolute risk of anastomotic leakage and computed ORs using logistic regression models with adjustment for potential confounders.RESULTS: Of the 18 190 patients with colon cancer, anastomotic leakage occurred in 1184 (6.5%). Glucocorticoid use overall was not associated with an increased risk of leakage (6.4% vs 6.9% among never-users; OR 1.05; 95% CI 0.89 to 1.23). Categories of oral, inhaled or intestinal-acting glucocorticoids did not greatly affect risk of leakage. Anastomotic leakage occurred in 695 (13.2%) of 5284 patients with rectal cancer. Glucocorticoid use overall slightly increased risk of leakage (14.6% vs 12.8% among never-users; OR 1.36, 95% CI 1.08 to 1.72). Results did not differ significantly within glucocorticoid categories.CONCLUSIONS: Preadmission glucocorticoids modestly increased the risk of anastomotic leakage mainly after rectal cancer resection. However, absolute risk differences were small and the clinical impact of glucocorticoid use may therefore be limited.",
author = "Ostenfeld, {Eva Bjerre} and Rune Erichsen and Baron, {John A} and Ole Thorlacius-Ussing and Iversen, {Lene Hjerrild} and Riis, {Anders H} and S{\o}rensen, {Henrik Toft} and {Danish Colorectal Cancer Group}",
note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",
year = "2015",
doi = "10.1136/bmjopen-2015-008045",
language = "English",
volume = "5",
pages = "e008045",
journal = "B M J Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "9",

}

RIS

TY - JOUR

T1 - Preadmission glucocorticoid use and anastomotic leakage after colon and rectal cancer resections

T2 - a Danish cohort study

AU - Ostenfeld, Eva Bjerre

AU - Erichsen, Rune

AU - Baron, John A

AU - Thorlacius-Ussing, Ole

AU - Iversen, Lene Hjerrild

AU - Riis, Anders H

AU - Sørensen, Henrik Toft

AU - Danish Colorectal Cancer Group

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2015

Y1 - 2015

N2 - OBJECTIVE: To examine whether preadmission glucocorticoid use increases the risk of anastomotic leakage after colon and rectal cancer resections.DESIGN: A population-based cohort study.SETTING: Denmark (2001-2011).PARTICIPANTS: We identified patients who had undergone a primary anastomosis after a colorectal cancer resection by linking medical registries. Participants who filled their most recent glucocorticoid prescription ≤90, 91-365 and >365 days before their surgery date were categorised as current, recent and former users, respectively.MAIN OUTCOME MEASURES: We calculated 30-day absolute risk of anastomotic leakage and computed ORs using logistic regression models with adjustment for potential confounders.RESULTS: Of the 18 190 patients with colon cancer, anastomotic leakage occurred in 1184 (6.5%). Glucocorticoid use overall was not associated with an increased risk of leakage (6.4% vs 6.9% among never-users; OR 1.05; 95% CI 0.89 to 1.23). Categories of oral, inhaled or intestinal-acting glucocorticoids did not greatly affect risk of leakage. Anastomotic leakage occurred in 695 (13.2%) of 5284 patients with rectal cancer. Glucocorticoid use overall slightly increased risk of leakage (14.6% vs 12.8% among never-users; OR 1.36, 95% CI 1.08 to 1.72). Results did not differ significantly within glucocorticoid categories.CONCLUSIONS: Preadmission glucocorticoids modestly increased the risk of anastomotic leakage mainly after rectal cancer resection. However, absolute risk differences were small and the clinical impact of glucocorticoid use may therefore be limited.

AB - OBJECTIVE: To examine whether preadmission glucocorticoid use increases the risk of anastomotic leakage after colon and rectal cancer resections.DESIGN: A population-based cohort study.SETTING: Denmark (2001-2011).PARTICIPANTS: We identified patients who had undergone a primary anastomosis after a colorectal cancer resection by linking medical registries. Participants who filled their most recent glucocorticoid prescription ≤90, 91-365 and >365 days before their surgery date were categorised as current, recent and former users, respectively.MAIN OUTCOME MEASURES: We calculated 30-day absolute risk of anastomotic leakage and computed ORs using logistic regression models with adjustment for potential confounders.RESULTS: Of the 18 190 patients with colon cancer, anastomotic leakage occurred in 1184 (6.5%). Glucocorticoid use overall was not associated with an increased risk of leakage (6.4% vs 6.9% among never-users; OR 1.05; 95% CI 0.89 to 1.23). Categories of oral, inhaled or intestinal-acting glucocorticoids did not greatly affect risk of leakage. Anastomotic leakage occurred in 695 (13.2%) of 5284 patients with rectal cancer. Glucocorticoid use overall slightly increased risk of leakage (14.6% vs 12.8% among never-users; OR 1.36, 95% CI 1.08 to 1.72). Results did not differ significantly within glucocorticoid categories.CONCLUSIONS: Preadmission glucocorticoids modestly increased the risk of anastomotic leakage mainly after rectal cancer resection. However, absolute risk differences were small and the clinical impact of glucocorticoid use may therefore be limited.

U2 - 10.1136/bmjopen-2015-008045

DO - 10.1136/bmjopen-2015-008045

M3 - Journal article

C2 - 26408282

VL - 5

SP - e008045

JO - B M J Open

JF - B M J Open

SN - 2044-6055

IS - 9

ER -